The BUDAPEST CRT Upgrade trial marked the pioneering attempt to evaluate the efficacy and safety of a cardiac resynchronization therapy (CRT) upgrade in comparison to intracardiac defibrillator (ICD)-only treatment. This evaluation was conducted in patients with heart failure and reduced ejection fraction (HFrEF) who already had a pacemaker or ICD and experienced intermittent or permanent RV pacing.
Researchers concluded that the implementation of cardiac resynchronization therapy with a defibrillator (CRT-D) as an upgrade has shown to decrease morbidity and mortality while also promoting the improvement of left ventricular reverse remodeling. This is particularly beneficial for patients with heart failure and reduced ejection fraction (HFrEF) who experience intermittent or permanent right ventricular (RV) pacing.
For more cardiology research news join our newsletter or follow us on Twitter, Facebook, LinkedIn or Instagram.
